Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia

Linong Ji, Yanmei Liu, Heng Miao, Yongli Xie, Ming Yang, Wei Wang, Yuting Mu, Ping Yan, Sharon Pan, Brett Lauring, Shu Liu, Susan Huyck, Yanping Qiu, Steven G Terra, Linong Ji, Yanmei Liu, Heng Miao, Yongli Xie, Ming Yang, Wei Wang, Yuting Mu, Ping Yan, Sharon Pan, Brett Lauring, Shu Liu, Susan Huyck, Yanping Qiu, Steven G Terra

Abstract

Aim: Phase III, randomized, double-blind study evaluating the efficacy and safety of ertugliflozin in Asian patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin, including evaluation in the China subpopulation.

Materials and methods: A 26-week, double-blind study of 506 Asian patients (80.2% from mainland China), randomized 1:1:1 to placebo, ertugliflozin 5- or 15 mg, was performed. Primary endpoint was change from baseline in HbA1c at week 26. Secondary endpoints were change from baseline at week 26 in fasting plasma glucose (FPG), body weight (BW), systolic/diastolic blood pressure (SBP/DBP), and proportion of patients with HbA1c <7.0%. Hypotheses for the primary endpoint and FPG and BW secondary endpoints were tested in the China subpopulation.

Results: At week 26, least squares mean (95% CI) change from baseline HbA1c was significantly greater with ertugliflozin 5- and 15 mg versus placebo: -1.0% (-1.1, -0.9), -0.9% (-1.0, -0.8), -0.2% (-0.3, -0.1), respectively. Ertugliflozin significantly reduced FPG, BW and SBP. Reductions in DBP with ertugliflozin were not significant. At week 26, 16.2%, 38.2% and 40.8% of patients had HbA1c <7.0% with placebo, ertugliflozin 5- and 15 mg, respectively. 59.3%, 56.5% and 53.3% of patients experienced adverse events with placebo, ertugliflozin 5- and 15 mg, respectively. Incidence of symptomatic hypoglycaemia was higher for ertugliflozin 15 mg vs placebo. Results in the China subpopulation were consistent.

Conclusions: Ertugliflozin significantly improved glycaemic control and reduced BW and SBP in Asian patients with T2DM. Ertugliflozin was generally well-tolerated. Results in the China subpopulation were consistent with the overall population. ClinicalTrials.gov: NCT02630706.

Keywords: Asia; SGLT2 inhibitor; ertugliflozin; type 2 diabetes mellitus.

Conflict of interest statement

Author contributions

All authors critically reviewed the draft manuscript and approved the final version of the manuscript for publication. M.Y., W.W., Y.M., S.P., P.Y. and S.G.T. were involved in the conception/design of the study. L.J., Y.L., H.M. and Y.X. were involved in the acquisition of data for the study. All authors were involved in data analysis and interpretation of the data.

© 2019 John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Least squares mean change from baseline in HbA1c over time for overall population. Based on cLDA model with fixed effects for treatment, time, antihyperglycaemic medication status at screening, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable. cLDA, constrained longitudinal data analysis; eGFR, estimated glomerular filtration rate; LS, least squares; SE, standard error
Figure 2
Figure 2
Efficacy outcomes in overall population: A, least squares mean change from baseline in HbA1c at week 26; B, proportion of patients with HbA1c

References

    1. International Diabetes Federation . IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017.
    1. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948‐959.
    1. Li H, Oldenburg B, Chamberlain C, et al. Diabetes prevalence and determinants in adults in China mainland from 2000 to 2010: a systematic review. Diabetes Res Clin Pract. 2012;98:226‐235.
    1. Fitchett D, Inzucchi SE, Lachin JM, et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J Am Coll Cardiol. 2018;71:364‐367.
    1. El Masri D, Ghosh S, Jaber LA. Safety and efficacy of sodium‐glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: a systematic review and meta‐analysis. Diabetes Res Clin Pract. 2018;137:83‐92.
    1. Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium‐glucose co‐transporter‐2 inhibitors as add‐on therapy to insulin for type 1 diabetes mellitus: systematic review and meta‐analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20:1755‐1761.
    1. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis. Diabetes Obes Metab. 2016;18:783‐794.
    1. Hsia DS, Grove O, Cefalu WT. An update on sodium‐glucose co‐transporter‐2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24:73‐79.
    1. Kalgutkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF‐04971729, a selective inhibitor of the sodium‐dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011;39:1609‐1619.
    1. Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF‐04971729) in healthy male subjects. Drug Metab Dispos. 2013;41:445‐456.
    1. FDA. Steglatro (ertugliflozin) Prescribing Information . Accessed March 2019.
    1. EMA. Ertugliflozin (Steglatro) Summary of Product Characteristics . Accessed March 2019.
    1. CADTH . CADTH Common Drug Review Submissions . Accessed February 2019.
    1. Australian Government Department of Health . Prescription Medicines: Registration of New Chemical Entities in Australia . Accessed February 2019.
    1. Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20:520‐529.
    1. Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20:1111‐1120.
    1. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm ‐ 2018 executive summary. Endocr Pract. 2018;24:91‐120.
    1. Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co‐initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther. 2018;9:253‐268.
    1. Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9:49‐66.
    1. Aronson R, Frias J, Goldman A, Darekar A, Lauring B, Terra SG. Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab. 2018;20:1453‐1460.
    1. Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19:721‐728.
    1. Hollander P, Liu J, Hill J, et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther. 2018;9:193‐207.
    1. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213‐226.
    1. Dagogo‐Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo‐controlled randomized study. Diabetes Obes Metab. 2018;20:530‐540.
    1. Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17:591‐598.
    1. Liu J, Tarasenko L, Terra SG, et al. Effects of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: a pooled analysis of placebo‐controlled studies. Diab Vasc Dis Res. 2019. In press.
    1. Liu J, Pong A, Huyck S, et al. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Diabetes. 2018;67(Supplement 1):1132‐P.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere